Toward Individualized Atherosclerosis Therapy: Clinical Endotypes, Programmable Therapeutics, and Delivery Constraints
Atherosclerosis remains the dominant substrate of atherosclerotic cardiovascular disease (ASCVD), yet recurrent events persist even when LDL cholesterol is driven to guideline targets, underscoring residual risk as a central limitation of contemporary prevention. This residual risk is not monolithic: It reflects mech...
Yun-Dong Peng, Rui Li, Huan Li et al.
· Medicine Bulletin · 0 citations